Risk factors for amphotericin b nephrotoxicity among children six months to eighteen years old admitted at the Philippine Children&rsquo;s Medical Center

Diosemil  L. Leyson-Guzman,; Alona  A. Briones,; Maria Rosario  S. Cruz,; Ma. Norma  V. Zamora,; Rachelle  C. Dela Cruz,

Risk factors for amphotericin b nephrotoxicity among children six months to eighteen years old admitted at the Philippine Children’s Medical Center

Diosemil L. Leyson-Guzman | Alona A. Briones | Maria Rosario S. Cruz | Ma. Norma V. Zamora | Rachelle C. Dela Cruz

Abstract:

BACKGROUND: Amphotericin B is used in pediatrics for severe fungal infections despite its known nephrotoxic side effects. Tubular injury and renal vasoconstriction range from 15-58% with exact risk factors that predispose children to developing these complications still undefined. OBJECTIVES: To determine the risk factors for nephrotoxicity with deoxycholate Amphotericin B treatment among children 6 months-18 years old at the Philippine Children‘s Medical Center from 2006- 2017 METHODS: This is a retrospective case-control study of 150 patients. Cases had decrease in eGFR by at least 25% and/or developed hypokalemia after at least one dose of Amphotericin. Those who did not develop nephrotoxicity were considered controls. Risk factors evaluated were age, sex, nutritional status, underlying medical condition, cumulative dose, concomitant use of nephrotoxic drugs used, treatment with diuretics and intravenous hydration. Results were analyzed using univariate and multivariate regression models. RESULTS: Using logistic regression, underlying malignancy had the highest odds ratio of 33.1 and nutritional status of z score=0 showed the lowest at 0.158. Duration of treatment >14 days had 1.75 times chance of developing nephrotoxicity while total cumulative dose >7.1 mg/kg had 1.5 times more chance of developing nephrotoxicity. Subjects given diuretics had 5.5 times more odds, while those not given concomitant nephrotoxic medications were 5.33% less likely to develop renal toxicity. CONCLUSION: Risk factors for nephrotoxicity were malignancy as an underlying medical condition, duration of amphotericin treatment of >14 days, cumulative dose >7.1 mg/kg and diuretic use. Normal nutritional status and no other concomitant nephrotoxic medication use had lesser odds of developing nephrotoxicity. RECOMMENDATION: Clinicians should consider these risk factors, institute measures to monitor occurrence of nephrotoxicity and the need for alternative fungal therapy in these children. With identification of the population at risk, prospective research on determining the specific onset of renal effects and possible intervention is recommended.

References:

Bes, D., Rosanova, M., Sberna, N., Arrizurieta, E. (2014). Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting. Pediatric Infectious Disease Journal, 33, 198–206.
Goldman, R., & Koren, G. (2004). Amphotericin B nephrotoxicity in children. Journal of Pediatric Hematology/Oncology, 26(7), 421–426.
Berdichevski, R., Luis, L. B., Crestana, L., & Manfro, R. C. (2006). Amphotericin B-related nephrotoxicity in low-risk patients. Brazilian Journal of Infectious Diseases, 10(2), 94–99.
Luber, A., Maa, L., Lam, M., & Guglielmo, B. J. (1999). Risk factors for amphotericin B-induced nephrotoxicity. Journal of Antimicrobial Chemotherapy, 43, 267–271.
Horwitz, E., Shavit, O., Shouval, R., Hoffman, A., Shapiro, M., & Moses, A. (2012). Evaluating real-life clinical and economic burden of amphotericin B deoxycholate adverse reactions. International Journal of Clinical Pharmacy, 34, 611–617.
Laborin, R. L., & Vargas, M. N. (2009). Amphotericin B: Side effects and toxicity. Revista Iberoamericana de Micología, 26(4), 223–227.
Bagnis, C., & Deray, G. (2002). Amphotericin B nephrotoxicity. Saudi Journal of Kidney Diseases and Transplantation, 13(4), 481–491.
Dutta, A., & Palazzi, D. (2012). Risk factors of amphotericin B toxicity in the non-neonatal pediatric population. Pediatric Infectious Disease Journal, 31(9), 910–914.
Fisher, M. A., Talbot, G. H., Maislin, G., et al. (1989). Risk factors for amphotericin B-associated nephrotoxicity. American Journal of Medicine, 87, 547–552.
Soler, Y., Plaza, N., & Prieto, M. (2013). pRIFLE (pediatric risk, injury, failure, loss, end stage renal disease) score identifies acute kidney injury and predicts mortality in critically ill children: A prospective study. Pediatric Critical Care Medicine, 14(4), 189–195.
Bates, D., Su, L., Yu, D., et al. (2001). Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney International, 60, 1452–1459.
Harbarth, S., Pestotnik, S., Lloyd, J., et al. (2001). The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. American Journal of Medicine, 111, 529–534.
Goldman, R., Ong, M., Wolpin, J., et al. (2007). Pharmacologic risk factors for amphotericin B nephrotoxicity in children. Journal of Clinical Pharmacology, 47, 1049–1054.